New findings could spark change in the way that some patients with multiple myeloma are treated.
The randomized, phase 2 GRIFFIN trial is yielding exciting results in the myeloma space, explained Peter Voorhees, M.D., a myeloma investigator at the Levine Cancer Institute.
The trial is investigating the addition of daratumumab to the regimen of Revlimid (lenalidomide), Velcade (bortezomib) and dexamethasone — a combination known as RVD – in patients with newly diagnosed myeloma who are eligible for a stem cell transplant. So far, the trial results are showing that the combination is well-tolerated with no unexpected side effects. The combination also had high response rate, with responses deepening as time goes on and even as patients move into the maintenance setting.
These results are all very promising, and down the line could even change the way that myeloma is treated, Voorhees said.
